This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Hypertension , diabetes and stroke in Afro - Caribbeans

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Hypertension is more common in Afro-Caribbeans than caucasian population in the UK.

  • monotherapy for hypertension - low dose diuretic or calcium channel blocker
    • Afro-caribbeans tend to develop low-renin, salt sensitive type hypertension. Monotherapy for hypertension with beta-blockers or ACE - inhibitors is less effective than low dose diuretics or a calcium channel blockers (1,3,4)

  • when a diuretic or a calcium channel blocker is used in combination with an ACE inhibitor of beta blocker, the treatment may be as efffective as in the general population (3). However a combination of a diuretic, a calcium channel blocker and an ACE inhibitor may be required (3)

Coronary artery disease occurs at only half to two-thirds of the national level. More Afro-Caribbean people die from stroke, heart failure and renal pathology secondary to hypertension.

Type 2 diabetes is more common in hypertensive Afro-Caribbeans.

Reference:

  1. Factfile (9/97). British Heart Foundation
  2. Marmot (1992). Primary prevention of stroke. Lancet 339.
  3. Drug and Therapeutics Bulletin (2001), 39(5), 37-40.
  4. NICE (August 2011). Hypertension - management of hypertension in adults in primary care.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.